Sugi Predict

Sugi Predict / Targets / LPXN

LPXN

Leupaxin · O60711 · LPXN on Sugi Atlas →

0 patent compounds predicted against LPXN, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to LPXN by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty PHASE4COMPLETED
A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants PHASE4COMPLETED
Half-Dose Depot Triptorelin Versus Reduced-Dose Daily Buserelin PHASE4COMPLETED
A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty PHASE3COMPLETED
Study of Lupron Depot In The Treatment of Central Precocious Puberty PHASE3COMPLETED
A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer PHASE3COMPLETED
A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids PHASE3COMPLETED
A Study of Leuprolide to Treat Prostate Cancer PHASE3COMPLETED
A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP) PHASE3COMPLETED
A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer PHASE3COMPLETED
Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty PHASE3ACTIVE_NOT_RECRUITING
Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer PHASE3COMPLETED
Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer PHASE3COMPLETED
A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer PHASE2COMPLETED
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer PHASE2COMPLETED
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease PHASE2RECRUITING
Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study PHASE2WITHDRAWN
A Study of Pharmacokinetic/Pharmacodynamic Profile of Orally Administered Leuprolide in Healthy Female Volunteers PHASE2COMPLETED
Generation of Positive Biological Samples to Leuprolide Acetate for Doping Control PHASE1COMPLETED
Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following SC Administration of DWJ108J in Patients With Prostate Cancer PHASE1UNKNOWN
Follicle-Stimulating Hormone (FSH) and the Onset of Puberty EARLY_PHASE1COMPLETED
Purification of Testis-Stimulating Factor in Precocious Puberty nanCOMPLETED
Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey Long-term Use Survey in Prostate Cancer Patients (96 Weeks) nanCOMPLETED
Leuprolide in Treating Adults With Hypogonadotropism nanCOMPLETED
A Comparison of the Microdose Leuprolide Protocol vs. Luteal Phase Ganirelix Protocol in Women Who Are or Who Are Predicted to be Low Responders nanCOMPLETED
Evaluation of Diet and Exercise in Prostate Cancer Patients nanCOMPLETED
Description of Relugolix Use in Patients With Prostate Cancer Within the VHA nanCOMPLETED
Observational Program to Assess Use of Intermittent Adjuvant Deprivation Therapy With Leuprorelin (Lucrin Depot) in Patients With Advanced Prostate Cancer (PCa) in Russia nanCOMPLETED
Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks) nanCOMPLETED
High-Dose Brachytherapy in Treating Patients With Prostate Cancer nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a LPXN binder may also engage these)

ProteinNameSimilarity
Q9N261 — 1.000 Q9N261 →
Q99N69 — 1.000 Q99N69 →
Q2TCH4 — 1.000 Q2TCH4 →
Q62219 — 0.999 Q62219 →
O43294 — 0.998 O43294 →
Q99PD6 — 0.995 Q99PD6 →
Q09476 — 0.993 Q09476 →
Q9Z1Z9 — 0.993 Q9Z1Z9 →
P49024 — 0.992 P49024 →
Q3MHZ4 — 0.992 Q3MHZ4 →
Q3TJD7 — 0.992 Q3TJD7 →
Q66H76 — 0.991 Q66H76 →
Q5R7I1 — 0.990 Q5R7I1 →
Q8VI36 — 0.989 Q8VI36 →
Q6P7E4 — 0.989 Q6P7E4 →
Q679P3 — 0.988 Q679P3 →
Q3SX40 — 0.988 Q3SX40 →
Q54NW4 — 0.987 Q54NW4 →
P49023 — 0.987 P49023 →
Q9NR12 — 0.986 Q9NR12 →
Q62920 — 0.985 Q62920 →
Q6INU3 — 0.985 Q6INU3 →
PDLIM5 PDZ and LIM domain protein 5 0.985 landscape →
O77775 — 0.985 O77775 →
P36202 — 0.983 P36202 →
Q8MML5 — 0.983 Q8MML5 →
Q9JKS4 — 0.983 Q9JKS4 →
Q5XI06 — 0.983 Q5XI06 →
Q9VTT9 — 0.983 Q9VTT9 →
KDM5B Lysine-specific demethylase 5B 0.983 landscape →